Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20191051 | 0.91 | AAK1 (0.53) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL26464168 | 0.88 | AAK1 (0.51) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL26013257 | 0.87 | AAK1 (0.50) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL22314538 | 0.87 | AAK1 (0.52) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL26013177 | 0.85 | AAK1 (0.48) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL6934738 | 0.83 | AAK1 (0.50) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL10177490 | 0.82 | DGAT1 (0.64) | AAK1DGAT1FFAR1ALPLGSK3A | |
| SCHEMBL22067624 | 0.82 | AAK1 (0.45) | AAK1DGAT1ALPLGSK3AGSK3B | |
| SCHEMBL20746298 | 0.82 | AAK1 (0.44) | AAK1DGAT1FFAR1ALPLLPL | |
| SCHEMBL22066642 | 0.81 | AAK1 (0.46) | AAK1DGAT1FFAR1ALPLLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | AAK1 3688/4885DGAT1 464/4885FFAR1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.